Identification of CB1 Ligands among Drugs, Phytochemicals and Natural-Like Compounds: Virtual Screening and In Vitro Verification

Adam Stasiulewicz, Anna Lesniak, Piotr Sętny, Magdalena Bujalska-Zadrożyń and Joanna I. Sulikowska*

ABSTRACT: Cannabinoid receptor type 1 (CB1) is an important modulator of many key physiological functions and thus a compelling molecular target. However, safe CB1 targeting is a non-trivial task. In recent years, there has been a surge of data indicating that drugs successfully used in the clinic for years (e.g., paracetamol) show CB1 activity. Moreover, there is a lot of promise in finding CB1 ligands in plants other than *Cannabis sativa*. In this study, we searched for possible CB1 activity among already existing drugs, their metabolites, phytochemicals, and natural-like molecules. We conducted two iterations of virtual screening, verifying the results with in vitro binding and functional assays. The in silico procedure consisted of a wide range of structure- and ligand-based methods, including docking, molecular dynamics, and quantitative structure–activity relationship (QSAR). As a result, we identified travoprost and ginkgetin as CB1 ligands, which provides a starting point for future research on the impact of their metabolites or preparations on the endocannabinoid system. Moreover, we found five natural-like compounds with submicromolar or low micromolar affinity to CB1, including one mixed partial agonist/antagonist viable for hit-to-lead phase. Finally, the computational procedure established in this work will be of use for future screening campaigns for novel CB1 ligands.

KEYWORDS: cannabinoid receptor, phytocannabinoids, travoprost, ginkgetin, docking, QSAR

1. INTRODUCTION

The endocannabinoid system (ECS) is one of the most important regulatory systems in the human organism. It is responsible for the control of a vast array of physiological processes and functions, including nociception, mood regulation, appetite, fat and glucose metabolism, neurogenesis and neurodegeneration, cell proliferation and many others. The most important protein of the ECS, cannabinoid receptor type 1 (CB1), is a well-established molecular target. Compounds acting via this receptor are present in approved drugs, clinical trial candidates or are under consideration at various preclinical levels.

CB1 ligands with different intrinsic activities are valuable for various therapeutic purposes. CB1 agonists or partial agonists are useful among others as analgetics and anti-emetic agents. CB1 antagonists/inverse agonists may act as anorectics or antiinflammatory agents. However, effective and safe CB1 targeting is a non-trivial task, as the ECS is a multi-purpose system. Although CB1 agonists, including phytocannabinoids, are generally well tolerated, their pharmacotherapeutic profile is not perfect. For example, long-term use of *Cannabis sativa* may come with a risk of cognitive impairment. On the other hand, CB1 antagonists/inverse agonists usage may cause serious psychiatric disorders, such as anxiety or depression.

To date, multiple ways to overcome the aforementioned obstacles have been proposed. Most of the adverse effects related to the modulation of CB1 activity are caused by the subpopulation of this receptor localized in the central nervous system. Thus, one of the possible solutions is to design peripheral CB1 ligands. Another prominent strategy is to utilize CB1 neutral antagonists instead of inverse agonists. CB1 allosteric modulation may be a promising direction as well.

It is often not realized that the most successful compounds acting via CB1 in a safe manner are among already known drugs. Paracetamol (acetaminophen), one of the most often used active substance all over the world, was proved to owe its analgesic activity in major part to anandamide reuptake inhibition and CB1 activation by its active metabolite—*N*-arachidonoylphenolamine (AM404). Other notable examples of pharmacologically relevant substances acting via CB1 or interacting with this receptor include metamizole (dipyrone), fenofibrate and raloxifene. Is is possible that there may be other active drug ingredients with considerable affinity toward CB1. If so, recognizing their mechanism of action may lead to...
more rational and thus safer use of those substances in pharmacotherapy. In addition, rational repurposing of drugs with known safety profiles may be implemented.

One of the most successful strategies of targeting the ECS is based on *Cannabis sativa* or its specific phytocannabinoids. While they have proved effective in many indications and are generally well tolerated, the therapy comes with a risk of addiction and adverse effects, such as memory impairment or cognitive dysfunctions caused by the long-term use. Thus, there is still room for improvement in this therapeutic area. Indeed, in recent years there have been numerous attempts to find phytocannabinoids in other plants. Alas, so far the results are not satisfactory enough, as the revealed compounds have only low or moderate affinities toward CB1, unsatisfactory intrinsic activity and their pharmacological relevance has not been fully determined. Therefore, there is a huge potential in finding new non-*Cannabis* phytocannabinoids with a more favorable pharmacological profile.

Because of its importance in the human organism and possible medical applications, CB1 has been a subject of great scientific interest. Many drug design projects, aimed at this crucial molecular target, were hindered by insufficient knowledge of its structure. In 2016, Hua et al. crystallized CB1 and elucidated its tertiary structure (Figure 1A). This allowed for better understanding of CB1 action and created a possibility for rational drug design. As of today, there are eight CB1 structures deposited in the Protein Data Bank (PDB) (Table 1). They bind six different ligands (Figure 1B) from four chemotypes and in some cases are complexed with G-protein or allosteric modulators. Accordingly, they represent diverse binding site conformations, providing a suitable ground for structure-based (SB) design or screening. Moreover, there are over 4000 records on $K_i$ values measured for CB1 ligands in the ChEMBL database, which correspond to over 2500 unique compounds with known binding affinities. Such quantity allows for rational utilization of ligand-based (LB) methods.

The aim of this study was to identify novel CB1 ligands among drugs, drug metabolites, phytochemicals, and related compounds. The elucidation of CB1 structure provided an excellent opportunity to screen a large number of compounds in a short time, using in silico methods. In this study, we utilized a wide range of computational techniques, combining both SB and LB approaches and evaluated the results of our predictions with in vitro binding and functional assays. As a result, we identified a drug active ingredient and a phytochemical compound as new CB1 ligands. Also, we found several hits among natural-like compounds, one of them being a suitable candidate for hit-to-lead stage. Moreover, the in silico procedure established in this study could be utilized in other future projects focusing on search for novel CB1 ligands.

Table 1. CB1 Structures Deposited in the PDB

| PDB ID | ligand       | intrinsic activity | additional features | method | resolution (Å) | references |
|--------|--------------|--------------------|---------------------|--------|----------------|------------|
| STGZ   | AM-6538      | antagonist         |                     | XRD    | 2.80           | 21         |
| 5U09   | taranabant   | inverse agonist    |                     | XRD    | 2.60           | 22         |
| 5XR8   | AM-841       | agonist            |                     | XRD    | 2.95           | 23         |
| 5XRA   | AM-11542     | agonist            |                     | XRD    | 2.80           | 23         |
| 6N4B   | MDMB-Fubinaca| agonist            | G-protein           | Cryo-EM| 3.00           | 24         |
| 6KPG   | AM-841       | agonist            | G-protein           | Cryo-EM| 3.00           | 26         |
| 6KQI   | CP-55,940    | agonist            | ORG27569 (NAM)     | XRD    | 3.25           | 25         |
| 7V5Z   | CP-55,940    | agonist            |                     | XRD    | 3.29           | 27         |

*Cryo-EM, cryoelectron microscopy; NAM, negative allosteric modulator; XRD, X-ray diffraction.*

![Figure 1. (A) CB1 binding site with bound AM-6538. Based on PDB ID: STGZ. (B) Structural formulas of six ligands present in CB1 structures deposited in the PDB. ECL2, extracellular loop 2; TM, transmembrane helix.](https://doi.org/10.1021/acschemneuro.2c00502)
2. RESULTS AND DISCUSSION

2.1. Double Iterative Screening. In order to find CB1 ligands among drugs, drug metabolites, and natural compounds, we conducted iterative screening that consisted of two major parts. The first iteration included initial virtual screening (VS) of small ligand libraries (~10,000 compounds total), with the focus on SB methods. This strategy was adopted to test whether SB techniques alone would be suitable for such non-trivial, hydrophobic molecular targets as CB1 (Figure S1) and to possibly increase chances for the identification of new CB1 ligands with considerably distinct chemotypes. The best candidates were evaluated in a cell-based displacement binding assay. The second iteration was planned based on the conclusions derived from the first one. Herein, we decided to combine LB and SB methods. This time, we screened a more vast chemical space of ~230,000 compounds, which also included the previously mentioned 10,000. The top scored molecules were verified in the in vitro binding assay.

2.1.1. First Iteration. The first iteration relied heavily on SB methods, mainly docking and molecular dynamics (MD). From the four CB1 structures available at the time (PDB IDs: 5TGZ, 5U09, 5XR8, and 5XRA), we selected one active CB1 conformation for this part of the study. As two such PDB entries, 5XR8 and 5XRA, are of similar quality and possess ligands from the same chemotype (Table 1 and Figure 1B), we chose 5XR8, because of its less truncated N-terminus, providing more complete structure for the sake of MD simulations. We screened three ligand libraries: DrugBank-approved, HMDB Drug Metabolites, and Biopurify Phytochemicals subsets from the ZINC database (~10,000 compounds). Initially, the molecules were docked to CB1 model based on PBD ID: 5XR8 using CDOCKER. The energies of the ligands were minimized in situ and the complexes were scored with PMF04 function. According to docking results and subsequent analysis, 40 ligands were selected for MD verification of their putative binding poses. The CB1–ligand complexes were embedded in lipid bilayer and full-atom MD simulations were conducted using GROMACS. In each case, we performed three repetitions per complex (see Methods). Based on the docking scores and root-mean-square deviation (rmsd) of the ligands’ heavy atoms from their initial geometries across MD simulations, we selected 22 drugs and phytochemical compounds for the in vitro binding assay (Table S1, Figures S2 and S3).

2.1.2. Second Iteration. In the second iteration, we combined SB and LB methods. The LB techniques were implemented to allow for the efficient screening of larger ligand libraries and to alleviate the inaccuracy of the SB approach when used alone for such a hydrophobic molecular target as CB1. In this part of the study, we screened ~230,000 compounds, including drugs, drug metabolites, phytochemicals, and natural-like compounds from the following libraries derived from the ZINC database: DrugBank-approved, HMDB Drug Metabolites, SMPDB, and ZINC biogenic subset (the libraries comprised all compounds from the first iteration). Based on the conclusions derived from the first iteration, we established and followed a multi-step workflow (Figure 2).

The first major part of the computational procedure involved filtration of physicochemical properties. The ligands were prepared using Schrödinger LigPrep, including generation of possible ionization states and tautomers, which resulted in ~300,000 compounds. Then, their physicochemical properties were computed with QikProp. For the filtration, we adopted our own criteria, mainly based on Lipinski’s and Veber’s rules, with less strict cutoffs for molecular weight (MW) (≤600 g/mol) and the number of rotatable bonds (≤20) as well as an
altered range for log $P$ (3–8). The first two changes were introduced due to multiple CB1 ligands, mainly antagonists, possessing MW above 500 g/mol and endocannabinoids having in some cases even up to 25 rotatable bonds. The modified criterion for log $P$ was meant to account for high hydrophobicity of CB1 orthosteric binding site and thus also CB1 ligands (Figure S4). The filtration allowed for considerable reduction of compounds pool to $\sim$120,000.

In the next part of the second iteration, we estimated the $pK_a$ values of the remaining compounds with machine learning quantitative structure–activity relationship (QSAR) models. This phase of the screening was conducted using Schrödinger AutoQSAR. We based our models on ChEMBL-deposited compounds with known $K_i$ values toward human CB1 (nearly 5000 entries at the time of the study). Those molecules were prepared in Schrödinger suite and then we applied the same criteria for the physicochemical properties as for the screening libraries. This filtration resulted in 2355 non-redundant compounds, based on which ten QSAR models were prepared. They exhibited desired binding affinity prediction capability, based on the statistical parameters (Table S2 and Figure S5). We utilized them to perform a consensus prediction of $pK_a$ values for the screening compounds. We retrieved molecules that were within the applicability domains of all QSAR models, as labelled by built-in function of Schrödinger AutoQSAR, and obtained the estimated average $pK_a$ value $\geq 6.5$.

The resulting $\sim$33,000 potential CB1 ligands were subjected to the next stage of the VS procedure, employing mainly SB methods. At this point, we divided the workflow into two branches. The first was aimed to identify potential CB1 agonists and the second—antagonists or inverse agonists (Figure 2B). In both branches, the remaining compounds were once again filtered based on their computed physicochemical properties, this time with specific criteria modified for potential agonists and antagonists (Table S3). In the case of agonists, we altered the cutoffs for MW ($\leq 500$ g/mol) and log $P$ (3.5–8). For antagonists, we reduced the maximal number of rotatable bonds to 10 (see Comments on the Virtual Screening Procedure).

The next step consisted of docking the two sets to specific CB1 models using Schrödinger Glide with standard precision (SP). Based on prior validation of binding affinity prediction (see Methods), we selected one active CB1 conformation for potential agonists (PDB ID: 5XR8) and one inactive for potential antagonists (PDB ID: 5TGZ). For each set, we performed two versions of docking—standard one and one with constraints on forming an H-bond with Ser383 hydroxyl group (Figure 2B), as this interaction was shown to be important for ligand binding in three out of four ligand chemotypes present in PDB-deposited CB1 structures (Figure 3). We retained the compounds with docking score values $\leq -10$. Then, the potential agonists were redocked using Glide extra precision (XP). In turn, due to differences in the binding site conformation (see Comments on the Virtual Screening Procedure), in the case of potential antagonists, we calculated the molecular mechanics-generalized Born surface area (MM-GBSA) binding free energies of the CB1–ligand complexes obtained from the Glide SP docking.

For the final analysis, we selected compounds with Glide XP docking score $\leq -12$ or MM-GBSA $\Delta G_{\text{bind}} \leq -85$ kcal/mol. Additionally, we took into account several potentially interesting drugs that obtained results close to fulfilling the criteria. The resulting molecules were subjected to an auxiliary structural clustering, which was of assistance especially for potential agonists, $\sim$250 of which met the previous screening criteria. Selected compounds were analyzed with the focus on...
their binding poses and interactions formed with the receptor. Also, we took into account docking scores, MM-GBSA $\Delta G_{\text{bind}}$ and QSAR-predicted $pK_i$ values. We aimed to select structurally diverse compounds. We identified several known CB1 and/or CB2 ligands or their close derivatives, which we did not take into account for further verification. Finally, the commercial availability of the most promising candidates was evaluated. As a result of this procedure, we hand-picked 23 compounds for the in vitro binding assay (Table 2, Table S4, Figures S6 and S7).

### 2.2. In Vitro Binding Affinity and Intrinsic Activity Assays

CB1 binding affinities of 45 compounds selected from both iterations of virtual screening were evaluated in the radioligand displacement assay. Seven ligands exhibited submicromolar or low micromolar affinities toward CB1 (Figure 4A,B). Two molecules from the first iteration showed low micromolar affinities: compound 9 (travoprost) obtained a $K_i$ value of 3.6 $\mu$M, while compound 15 (ginkgetin)—8.6 $\mu$M. The most potent CB1 ligand identified during the second iteration, compound 30, exhibited submicromolar affinity of 0.8 $\mu$M. Four other ligands from the second iteration, compounds 32, 34, 38, and 43 obtained low micromolar $K_i$ values of 6.8, 2.7, 2.5, and 6.6 $\mu$M, respectively. Compounds 32 and 34 were tested as racemic mixtures. Thus, their specific enantiomers identified during VS could possess lower $K_i$ values (Table 3). The other compounds obtained $K_i$ values >10 $\mu$M or showed no affinity toward CB1 (Tables S5 and S6).

Intrinsic activities of seven identified CB1 ligands were evaluated in the [3H]GTP$_\gamma$S ([3H]guanosine 5'-(y-thio)-triphosphate) assay (Figure 4C,D and Table 4). Compounds 9, 15, 32, 34, 38, and 43 were determined to act as agonists, with 34 and 43 obtaining IC$_{50}$ values of 3.7 and 1.9 $\mu$M, respectively. Compound 30 showed interesting functional activity of mixed CB1 partial agonist/antagonist, with EC$_{50}$ = 0.42 $\mu$M and IC$_{50}$ = 2.1 $\mu$M.

### 2.3. Analysis of the Binding Modes

Seven compounds that exhibited the highest binding affinities toward CB1 were analyzed in detail regarding their putative binding modes. The ligands from the first iteration of VS were docked to CB1 active conformation based on PDB ID: 5XR8. Compound 9 forms H-bonds with Ser383 and Thr197 as well as multiple weak hydrophobic interactions (Figure 5A,B). Interestingly, binding mode of 9 relies heavily on H-bonds and lacks $\pi$-$\pi$ interactions with several Phe residues present in the binding site, which are usually crucial for CB1–ligand complexes (Figure 3). On the other hand, compound 15 creates H-bonds with Ser383 and Cys386 but also $\pi$-$\pi$ interactions with Phe174, Phe200, Phe268, Trp279, and Phe379, and additionally other weak hydrophobic interactions (Figure 5C,D). This binding mode is more alike to those observed in PDB-deposited structures (Figure 3), rather than the one discussed in the case of compound 9. Notably, both ligands maintained their putative binding modes during MD simulations (Figure S8). Importantly, compound 9 showed promising results during the second iteration (Table S7). However, in this case it achieved desired scores for the inactive CB1 conformation (PDB ID: 5STGZ) and assumed a distinct binding mode (Figure S9).

Compounds 30, 32, 34, 38, and 43 were docked to active and inactive CB1 conformations, based on PDB IDs: 5XR8 and 5STGZ, respectively. Moreover, we also conducted docking with constraints on forming an H-bond with Ser383. Additionally, in the case of active CB1 conformation, docking was performed with SP and XP Glide modes. Thus, we obtained multiple CB1–ligand complexes for the candidates from the second iteration. Compounds 30 and 32 were

### Table 2. Results of the Second Iteration of Virtual Screening

| ID | pred. $pK_i$ | SP DS | XP DS | SP DS | XP DS | SP DS | MM-GBSA $\Delta G_{\text{bind}}$ (kcal/mol) | SP-constraints | MM-GBSA-constraints $\Delta G_{\text{bind}}$ (kcal/mol) |
|----|-------------|-------|-------|-------|-------|-------|---------------------------------|---------------|---------------------------------|
| 23 | 6.7         | −11.3 | −13.4 | −11.3 | −13.4 | −9.6  | −10.0                          | −44.8         |
| 24 | 6.5         | −10.7 | −13.4 | −10.2 | −13.5 | −8.4  | −7.9                           |
| 25 | 6.5         | −11.3 | −13.1 | −13.0 | −8.9  | −7.4  |
| 26 | 6.7         | −10.5 | −13.1 | −10.8 | −13.0 | −8.9  | −9.4                           |
| 27 | 6.6         | −11.9 | −13.0 | −13.7 | −9.3  | −9.4  |
| 28 | 6.6         | −12.2 | −13.7 | −12.0 | −13.7 | −9.3  |
| 29 | 6.6         | −10.1 | −12.5 | −10.3 | −12.4 | −8.8  |
| 30 | 6.5         | −10.9 | −14.0 | −10.7 | −13.7 | −8.9  |
| 31 | 6.6         | −10.4 | −13.2 | −13.0 | −9.5  | −10.1 |
| 32 | 6.5         | −12.0 | −12.3 | −12.1 | −13.0 | −11.2 |
| 33 | 6.6         | −10.1 | −11.6 | −11.2 | −59.6 | −4.7  |
| 34 | 6.5         | −9.6  | −10.1 | −85.0 | −10.0 | −86.7 |
| 35 | 6.6         | −10.3 | −93.7 | −10.2 | −95.5 |
| 36 | 6.6         | −11.2 | −80.7 | −11.4 | −91.5 |
| 37 | 6.8         | −11.8 | −93.9 | −10.5 | −86.3 |
| 38 | 6.6         | −11.0 | −11.9 | −10.0 | −10.2 | −8.5  |
| 39 | 6.7         | −10.8 | −83.4 | −10.2 | −85.5 |
| 40 | 6.7         | −11.9 | −85.2 | −12.0 | −62.5 |
| 41 | 6.6         | −10.6 | −85.9 | −10.3 | −82.8 |
| 42 | 6.7         | −7.4  | −10.7 | −89.0 | −8.5  |
| 43 | 6.5         | −9.6  | −10.7 | −86.0 | −11.4 | −82.9 |
| 44 | 6.8         | −11.3 | −10.0 | −6.4  | −10.3 | −8.7  |
| 45 | 6.6         | −8.3  | −11.5 | −71.3 | −11.5 | −71.1 |

*DS, docking score.*
selected because of their high docking scores for CB1 active conformation. Compounds 34, 38 and 43 achieved desired docking scores and ΔGbind for inactive CB1 conformation. Interestingly, 32 showed also promising results for the inactive binding site conformation (5TGZ), while 38—for the active one (5XR8).

Compounds 30, 34, and 43 assumed consistent putative binding modes, regardless of the docking settings, and exhibited only small differences in conformations and interaction patterns. Compound 32 showed the same pose in three versions of docking (SP, SP with constraints, and XP with constraints) while an alternative one for XP. In turn,
Compound 38 adopted three different binding poses, depending on CB1 conformation and settings.

Compound 30 forms H-bonds with either Ser383 or Phe108. Additionally, this ligand maintains multiple π–π interactions with Phe170, Phe174, His178, Phe189, Phe268, and Trp279 (Figure 6A–C). The binding modes of compounds 34 and 43 are rather scarce in terms of the number of strong contacts, especially of the π-stacking character. Both ligands form H-bonds with Met103 and Ser383 and, in the case of compound 34, also a π–π interaction with Phe102 (Figure 6D–I). The more prevalent putative pose of compound 32 forms H-bonds with Ile267, Lys376, and Ser383 as well as π–π interactions with Phe170, His178, Phe200, Phe268, and Phe379 (Figure 7A–D). On the other hand, the second predicted pose displays a sparse interaction pattern including H-bonds with Thr197 and Ser383, and π–π interaction with His178 (Figure 7E,F).

### Table 4. Results of the Intrinsic Activity Determination with the [35S]GTPγS assay

| ID | ZINC ID                      | name                | CB1 inhibition pIC_{50} | IC_{50} (μM, 95% CI) | CB1 stimulation pEC_{50} | EC_{50} (μM, 95% CI) | E_{max} (%) |
|----|------------------------------|---------------------|-------------------------|----------------------|--------------------------|-----------------------|-------------|
| 9  | ZINC000004474682             | travoprost          | 3.64 ± 0.30             | 232 (34–782)         | 126.2 ± 5.0              | 6.38 ± 0.26          |
| 15 | ZINC000001531664             | ginkgetin           | 4.20 ± 0.16             | 63 (29–144)          | 0.42 (0.12–1.48)         | 126.2 ± 5.0          |
| 30 | ZINC00017658088              |                     | 5.68 ± 0.06             | 2.1 (1.5–2.7)        |                          |                       |
| 32a| ZINC000824654662             |                     | 4.48 ± 0.11             | 40 (23–71)           |                          |                       |
| 34a| ZINC000001832514             |                     | 5.43 ± 0.08             | 3.7 (2.6–5.5)        |                          |                       |
| 38 | ZINC000006040794             |                     | 3.85 ± 0.28             | 140 (36–601)         |                          |                       |
| 43 | ZINC000263585252             |                     | 5.73 ± 0.09             | 1.9 (1.2–2.9)        |                          |                       |
| 38a| ZINC000001540228             | rimonabant (reference) | 8.88 ± 0.18             | 0.0013 (0.0005–0.0032) |                          |                       |

Notes:

- **a**: Racemic mixture.

Figure 5. Two most potent CB1 ligands from the first iteration—travoprost (compound 9, ZINC000004474682) (A,B) and ginkgetin (15, ZINC000001531664) (C,D). Putative poses and binding modes obtained from docking to PDB ID: 5XR8. Ligands are depicted in green stick representation, amino acids that are crucial for ligand binding—grey stick representation. Part of TM6 not shown to increase readability.
the pyridine core, some of the \(\pi-\pi\) interactions occur consistently, including those with the side chains of Phe102, Phe170, and Phe268. In some cases compound 38 forms H-bond with Ser383 (Figure S10).

2.4. Prediction of Pharmacological and Toxicological Properties. Additionally to the binding affinity and intrinsic activity determination, for the newly identified CB1 ligands, we assessed pharmacological and toxicological properties to gain more insight into their potential for further optimization or utilization. Because travoprost, as an approved drug, is a well-inspected compound, we excluded it from this part of the study.

Pharmacological properties were estimated using SwissADME server. Selected properties are shown in Table S1. The putative binding modes of compounds 30, 34, and 43 are visualized in Figure 6. The ligands are depicted in green stick representation, amino acids that are crucial for ligand binding—grey stick representation. Purple arrow—H-bond; green line—\(\pi-\pi\) interaction. Parts of TM6 and TM7 not shown to increase readability.
Figure 7. Putative binding modes of compound 32 (ZINC000824654462). (A) The more prevalent pose, obtained from docking with Glide XP with constraints on forming an H-bond with Ser383. 2D interaction schemes from docking with Glide XP with constraints (B), SP (C), and SP with constraints (D). Panels E, F show the second pose encountered in complex from Glide XP docking. Ligands are depicted in green stick representation, amino acids that are crucial for ligand binding—grey stick representation. Purple arrow—H-bond; green line—π–π interaction. Part of TM6 not shown to increase readability.
5. We considered water solubility, gastrointestinal (GI) absorption, blood-brain barrier (BBB) permeation, P-glycoprotein (Pgp) binding and inhibition of the most important cytochrome P450 isozymes. As expected, because of high hydrophobicity, the ligands exhibit only moderate or poor solubility. Interestingly, all compounds were predicted to be unable to cross the BBB, which is a very desired trait in terms of the advantages of CB1 peripheral ligands. Such compounds could display better safety profile while still being poor solubility. Interestingly, all compounds were predicted to potentially exhibit developmental toxicity and Ames mutagenicity, for instance, compound 33 was consistently predicted as potentially mutagenic by both programs. In this case, Toxtree algorithms based their rating on the presence of alkyl carbamate moiety. Although this feature is also present among some approved drugs, it raises more substantial concerns and should be considered for further decision making on potential optimization. Other compounds raised no mutagenicity concerns or were flagged by only a single method.

2.5. Significance of the Results, Future Directions, and Limitations. Among drug active ingredients, travoprost (compound 9) was found to possess low micromolar affinity to CB1. However, the promising Kᵢ value did not convert to a relevant result in the functional assay. Nevertheless, travoprost is a prodrug, utilized in the treatment of ocular hypertension, including glaucoma. After topical administration it is hydrolyzed to its active metabolite—travoprost free acid. This compound acts as a FP prostanoid receptor agonist. However, its exact mechanism of action has not yet been determined. It was proved that CB1 takes part in the regulation of intraocular pressure and both CB1 agonists and antagonists could alleviate intraocular hypertension through different mechanisms. Thus, conducting studies regarding travoprost free acid’s impact on ECS may be a promising direction.

The most potent phytochemical encountered during the VS, ginkgetin (compound 15), is a biflavone found most notably in *Ginkgo biloba* but also in several other plants. Ginkgetin exhibits a wide range of therapeutic properties, including neuroprotective, anti-adipogenic, anti-inflammatory, anti-oxidant, anti-microbial, and anti-cancer actions. Similarly to travoprost, despite low micromolar affinity to CB1, ginkgetin

Table 5. Selected Pharmacological Parameters Estimated for Newly Identified CB1 Ligands†

| ID  | ZINC ID     | water solubility | cytochrome P450 inhibition | cytochrome P450 inhibition | cytochrome P450 inhibition | cytochrome P450 inhibition | cytochrome P450 inhibition | cytochrome P450 inhibition | cytochrome P450 inhibition |
|-----|-------------|------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| 15  | ZINC000001531664 | LogS = -7.17     | low                       | moderate                 | high                      | yes                       | yes                       | no                        | no                        |
| 30  | ZINC000217658088 | LogS = -6.93     | low                       | moderate                 | high                      | yes                       | yes                       | yes                       | yes                       |
| 32  | ZINC000824654462 | LogS = -5.01     | low                       | moderate                 | high                      | yes                       | yes                       | yes                       | yes                       |
| 34  | ZINC000001832514 | LogS = -6.63     | low                       | moderate                 | high                      | yes                       | yes                       | yes                       | yes                       |
| 38  | ZINC00006040794  | LogS = -5.90     | low                       | moderate                 | high                      | Yes                       | Yes                       | no                        | yes                       |
| 43  | ZINC000263585252 | LogS = -4.99     | high                      | negligible               | high                      | yes                       | yes                       | yes                       | yes                       |

†BBB, blood-brain barrier; CYP1A2, cytochrome P450 1A2; ESOL, Estimated SOLubility; GI, gastrointestinal; Pgp, P-glycoprotein.

Table 6. Results of the Toxicity Prediction for the New CB1 Ligands Identified among Natural and Natural-like Compounds†

| ID  | ZINC ID     | Kroes TTC | Ames mutagenicity | Ames mutagenicity | Ames mutagenicity | Ames mutagenicity | Ames mutagenicity | Ames mutagenicity | Ames mutagenicity | Ames mutagenicity |
|-----|-------------|-----------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| 15  | ZINC000001531664 | 0.23      | positive          | structural alert | 0.14             | positive          | structural alert | 0.73             | positive          |
| 30  | ZINC000217658088 | 0.21      | positive          | structural alert | 0.19             | positive          | structural alert | 0.76             | positive          |
| 32  | ZINC000824654462 | 0.71      | positive          | structural alert | 0.51             | positive          | structural alert | 0.64             | positive          |
| 34  | ZINC0000001835214 | 0.51      | positive          | structural alert | 0.44             | positive          | structural alert | 0.44             | positive          |

†Kroes TTC, threshold of toxicological concern.
was found to possess insignificant functional activity. However, it is worth to bear in mind the entourage effect. Non-cannabinoid compounds are able to improve the pharmacological profiles of cannabinoid receptor ligands when used in combination. Thus, it is worth to conduct further research on the extracts from specific preparations of plants containing ginkgetin. This could be especially interesting in the context of some properties shared by ginkgetin and CB1 antagonists, namely anti-adipogenic and anti-inflammatory actions.

Several natural-like compounds exhibited low micromolar affinities toward CB1, but most importantly, compound 30 achieved a $K_i$ value of 800 nM. To the best of our knowledge, this molecule represents a new chemotype of CB1 ligands. Moreover, it serves as a rare example of a mixed CB1 partial agonist/antagonist. Therefore, despite moderate binding affinity, compound 30 is an interesting hit and could be introduced to hit-to-lead stage.

The structural distinctiveness of compound 30, with respect to established CB1 ligands, is especially valuable in giving prospect for safe modulation of this specific receptor. Although multiple compounds with high affinities toward CB1 are known, they usually struggle with various issues, most notably with CB1-related adverse effects. Thus, multiple attempts, and consequently—diverse chemotypes among hits and leads might be needed to design a safe CB1 ligand.

Moreover, compound 30 is valuable due to its rare functional activity. Mixed agonists/antagonists are known to normalize the functions of the affected system. For example, pindolol, a $\beta$-adrenoreceptor antagonist, acts also as a partial agonist which is responsible for its intrinsic sympathomimetic activity. Conversely, CB1 partial agonists/antagonists could be very valuable due to the regulatory character of the ECS. In the case of CB1, such functional activity was observed under certain conditions for several tetrahydrocannabinol (THC) derivatives, for example $\Delta 9$-THC or O-823. Therefore, identification of CB1 partial agonist/antagonist representing another chemotype is a significant step toward rational design of such CB1 ligands.

Apart from $K_i$ improvement, the major challenge of compound 30 optimization would lie in its high log $P$ (5.2). However, such hydrophobicity is a standard issue for CB1 ligands (e.g. 5.8 for dronabinol). Moreover, high log $P$ is a problem that medicinal chemistry community has been able to successfully tackle in multiple hit-to-lead projects.

### 2.6. Comments on the Virtual Screening Procedure.

Utilization of a wide range of in silico methods across the two VS iterations allowed us to gain a valuable insight into the effectiveness of specific computational techniques in combination with CB1, a highly hydrophobic, non-trivial molecular target. The first iteration showed that solely SB methods struggle with a large amount of false positives. This issue was expected, nevertheless we decided to take the risk in order to increase the chances of encountering new chemotypes of CB1 ligands. The difficulties are caused mainly by the high hydrophobicity of CB1 orthosteric binding site (Figure S1). This hinders proper pose prediction as well as binding affinity estimation because of limited performance of most docking programs and scoring functions in the case of very lipophilic pockets.

A strategy to increase the true positive rate involves a combination of SB and LB methods. However, this approach comes with a cost of decreasing the chances of encountering new chemotypes and increasing the number of false negatives.

We employed this strategy in the second iteration, which indeed allowed us to obtain a higher percentage of ligands with relevant $K_i$ among the finally selected compounds (22 vs 9%, in comparison to SB only approach, respectively). Because the ligand set screened during the second iteration was broader than the one considered during the first iteration, a precise comparison between both approaches can not be made. However, focusing on in silico results of the second iteration screening limited to compounds considered during the first iteration shows that combination of SB and LB methods effectively tackled the false positives’ problem, rating highly only travoprost (Table S7).

The study also allowed us to draw conclusions regarding the ability of specific techniques to cope with troublesome CB1 docking. During the course of both iterations we utilized two docking programs—CDOCKER and Glide. They proved to perform quite similarly, both struggling with the hydrophobic binding site. Overall, Glide produced slightly better results in terms of the identification of CB1 ligands, as shown by $K_i$ values obtained in the second iteration. Moreover, according to results of the second iteration’s in silico validation, in the case of many CB1 conformations, Glide SP exhibited similar or even superior ability to order ligands based on their binding affinities compared to Glide XP or MM-GBSA. Importantly, Glide XP docking performed for the purpose of validation was independent of SP docking, providing more adequate data for comparison than the sequential screening. What is more, Glide SP obtained high enrichment factors (EFs) for most of the CB1 structures, with EF$_{5\%}$ >20 for four and >10 for six out of seven tested CB1 conformations (Supporting Information S2). It is also worth to note the difficulties of docking programs in terms of proper binding pose prediction in some cases. This was caused mainly by non-specific $\pi-\pi$ interactions with numerous Phe side chains in the CB1 binding site and was particularly evident for symmetrical-like ligands which possess aromatic rings in two or three vertices, for example taranabant or compound 38.

In one of the last steps of the second iteration, we applied diverse cutoffs for physicochemical properties filtration (Table S3) as well as utilized Glide XP or MM-GBSA for potential CB1 agonists and antagonists (Figure 2B). The decision regarding the thresholds change for agonists was caused by the smaller volume of the active conformation of CB1 binding site. Thus, MW above 500 g/mol is attributed mainly to CB1 antagonists/inverse agonists. Also, the smaller volume of active CB1 conformation allows for the influx of even fewer water molecules to the binding site compared to the inactive conformation, which is already hardly accessible to the extracellular solvent. This imposes usually higher minimal hydrophobicity of CB1 agonists. Reduction of the maximal number of rotatable bonds to 10 for potential antagonists was caused by the occurrence of the higher values only in endocannabinoid-like CB1 agonists. The reasoning behind the utilization of either Glide XP or MM-GBSA was based on validation results obtained during the second iteration. Both methods achieved high EFs for different CB1 models. In particular, MM-GBSA proved effective especially in the case of inactive geometry, represented by PDB ID: 5TGZ (EF$_{1\%}$ = 32.0), whereas Glide XP—for several active conformations: 5XR8 (EF$_{1\%}$ = 32.0), 5XRA (EF$_{1\%}$ = 24.0), and 6KQJ (EF$_{1\%}$ = 20.0) (Supporting Information S2). This may be also explained by the disparity in the size of the orthosteric binding site between CB1 conformations and the

https://doi.org/10.1021/acschemneuro.2c00502
subsequent exposure to solvent, as discussed above. As MM-GBSA is a method more accurate in terms of mimicking realistic solvent influence, it is reasonable that it copes better with more spacious binding site but struggles with the exceptionally lipophylic one.

Herein, we focused only on previously unidentified CB1 ligands with moderate to low affinity. However, it is worth to note that among the compounds placed highly by various methods during the second iteration, we encountered several known, potent CB1 ligands (Table 7). This includes compounds with very high affinity, for example rimonabant and nabilone, and the ones with moderately high affinity, such as bazedoxifene. Moreover, we encountered a few cannabinoids, mainly derivatives of cannabinol, with unspecified affinity toward CB1. This serves as an additional proof of concept and shows that the VS procedure is suitable to identify compounds with high affinity. Accordingly, we believe that the VS workflow used in the second iteration is also able to detect new, very potent compounds. To maximize the chances for obtaining such results, the final set selected for in vitro verification should include ligands that achieved both high docking scores or MM-GBSA binding energies and pKi values. While we would ideally expect pKi values above 7. This suggests that there is a low probability of encountering any other CB1 ligands among the screened libraries but also that the procedure could be successfully employed to seek for potent CB1 ligands among other compound sets.

Our computational procedure was established to identify new, possibly potent and structurally diverse CB1 ligands. Although we utilized active and inactive CB1 conformations and divided compounds into potential agonists and antagonists at specific stages, these actions were taken mainly for the sake of the aforementioned aims. It is important to state that in silico methods utilized in this study are not suited for reliable intrinsic activity estimation. This was confirmed by the discrepancy between loose, computational predictions and the [35S]GTPγS assay. Namely, out of seven identified CB1 ligands, two appeared in silico as possible agonists (compounds 15 and 30), two as antagonists (34 and 43), and the latter three (9, 32 and 38) showed ambiguous results. Therefore, estimating functional activity based on VS methods has to be taken with caution. Nevertheless, other, more time-costly in silico approaches, developed specifically for the discrimination of ligand efficacy, have been demonstrated for CB1.57

3. CONCLUSIONS

We conducted a double-iterative, multi-step, computational screening to seek for novel CB1 ligands among active drug ingredients, their metabolites, phytochemicals, and natural-like compounds. We selected 45 candidates for verification with an in vitro binding assay and, in the case of specific compounds, also with a functional assay. We identified travoprost and ginkgetin as CB1 ligands with low micromolar affinity. This finding may act as a starting point for further research on the impact of metabolites or preparations of these compounds on ECS. Moreover, we identified five natural-like compounds with submicromolar or low micromolar affinity toward CB1. The

Table 7. Examples of Known CB1 Ligands or Cannabinoids Identified during the Second Iteration of Virtual Screeninga

| ZINC ID | name | SP pred. | XP pred. | SP constraints | XP constraints | MM-GBSA ΔGbind (kcal/mol) | ZINC000001540228 rimonabant 8.2 | ZINC000001542930 nabilone 8.7 | ZINC000001895505 bazedoxifene 6.1 |
|--------|------|----------|----------|----------------|----------------|--------------------------|---------------------------------|---------------------------------|---------------------------------|
| 5XR8   |      | 35.8     | 35.8     | −11.6          | −11.6          | −6.9                     | 7.7                             | 6.2                             | 6.1                             |
| S5     |      | 35.8     | 35.8     | −6.5           | −6.5           | −8.2                     | 7.7                             | 6.2                             | 6.1                             |
| DS     |      | 35.8     | 35.8     | −6.9           | −6.9           | −8.2                     | 7.7                             | 6.2                             | 6.1                             |

a DS, docking score.
most potent CB1 ligand found, compound 30 (ZINC000217830653), because of its structural distinctiveness and rare mixed partial agonist/antagonist functional activity, could be considered in future hit-to-lead endeavours. Finally, the computational procedure established during this work will be of use for other VS campaigns aimed to search for novel CB1 ligands, especially in broader, synthetic libraries.

4. METHODS

4.1. First Iteration of Virtual Screening. The first iteration of virtual screening included docking with BIOVIA Discovery Studio 2018 and subsequent verification of the results with molecular dynamics in CHARMM-GUI Membrane Builder.

Screening compounds were downloaded from the ZINC15 database. The molecules were prepared in BIOVIA Discovery Studio 2018 using Prepare Ligands protocol with the generation of possible ionization states in pH 7.5 ± 1. The CB1 model based on PDB ID: 5XR8 was prepared with Prepare Proteins protocol. A spherical gridbox with a radius of 12 Å was created around the crystal ligand. Docking was conducted using CDOCKER with the maximum of ten poses saved per compound. Ligands were scored with PMF04 function. For the best pose for each docked molecule, the energy of the ligand was minimized with In Situ Ligand Minimization protocol. The obtained complexes were rescored with PMF04 function.

Selected CB1–ligand complexes were subjected to MD verification. Using Discovery Studio, we reverted the point mutations present in PDB ID: 5XR8 crystal structure, removed the fusion protein and reconstructed the intracellular loop 3 (ICL3) with Prepare Protein. A spherical gridbox with a radius of 12 Å was created around the crystal ligand. Docking was conducted using CDOCKER with the maximum of ten poses saved per compound. Ligands were scored with PMF04 function. For the best pose for each docked molecule, the energy of the ligand was minimized with In Situ Ligand Minimization protocol. The obtained complexes were rescored with PMF04 function.

Selected CB1–ligand complexes were subjected to MD verification. Using Discovery Studio, we reverted the point mutations present in PDB ID: 5XR8 crystal structure, removed the fusion protein and reconstructed the intracellular loop 3 (ICL3) with Prepare Protein protocol, based on the human CB1 sequence from UniProt. We utilized CHARMM-GUI Membrane Builder using Prepare Ligands protocol with the generation of possible ionization states in pH 7.5 ± 1. The CB1 model based on PDB ID: 5XR8 was prepared with Prepare Proteins protocol. A spherical gridbox with a radius of 12 Å was created around the crystal ligand. Docking was conducted using CDOCKER with the maximum of ten poses saved per compound. Ligands were scored with PMF04 function. For the best pose for each docked molecule, the energy of the ligand was minimized with In Situ Ligand Minimization protocol. The obtained complexes were rescored with PMF04 function.

4.2. Second Iteration of Virtual Screening. 4.2.1. Preparation of Ligands and Proteins. Screening compounds’ libraries were downloaded from the ZINC15 database. The classification of compounds as "natural-like" was based on the criteria established by the ZINC database for the assembly of its biogenics libraries. Test CB1 ligands were downloaded from PubChem. Compounds were prepared in Schrödinger Maestro 2017-1 software using LigPrep with generation of possible protonation states in the pH range 7.0 ± 2.0 with Epik and generation of possible tautomeric forms.

The CB1 structures were downloaded from the PDB. They were prepared in Maestro 2017-1 with Protein Preparation Wizard. Water molecules and other redundant, post-crystallization small molecules were removed. The CB1 structures were preprocessed, including the addition of hydrogen atoms and the generation of probable protonation states using Epik in the pH 7.0 ± 2.0. The H-bond assignment was optimized using PROPKA and structures were minimized using the OPLS3 force field.

4.2.2. Physicochemical Properties Filteration and QSAR. Initial preparation of compounds for the QSAR part of the study included the calculation of their physicochemical properties with Schrödinger QikProp. Then, they were filtered with a custom set of criteria that included the combination of properties from Lipinski’s rules and Veber’s rules and properties observed for most of the CB1 ligands (Figure S4): MW ≤ 600 g/mol; log P < 3; number of hydrogen bond acceptors ≤ 10; number of hydrogen bond donors ≤ 5; number of rotatable bonds ≤ 20, and polar surface area (PSA) ≤ 140 Å².

Generation of QSAR models and subsequent screening were performed with Schrödinger AutoQSAR. Training and test compounds for QSAR models were downloaded from the ChEMBL database. We selected 2549 compounds with Kᵢ values known for human CB1. Compounds were prepared in LigPrep without generation of protonation states or tautomers. Then, we generated probable protonation states and tautomeric forms in a separate Epik protocol in the pH 7.0 ± 2.0 with the maximum number of output structures per molecule set to 1. Physicochemical properties of prepared training/test compounds were calculated with QikProp. Then, we filtered compounds with the same set of criteria as the screening compounds, leaving 2355 training/test compounds. We used AutoQSAR protocol to generate QSAR models. Random training set was set to 75% compounds. Prediction property was set to pKᵢ. Consensus prediction of pKᵢ values was performed for the screening compounds by taking an average for all QSAR models. Only results with Domain Alert = 0 were kept.

4.2.3. Docking and MM-GBSA. Docking was conducted in Schrödinger Maestro 2017-1. The first step consisted of preparation of grid files for the previously prepared CB1 structures. We utilized Receptor Grid Generation Tool and created grids using ligands as the grids’ centers. For each CB1 structure, two grid files were created—a standard one and one with constraints for the formation of H-bonds with Ser383 hydroxyl group.

The docking itself was conducted using Glide with SP and XP modes. One best pose for ligand in each docking was saved. MM-GBSA binding free energy calculations were performed using Prime MM-GBSA with VSGB solvation model and OPLS3 force field. Before the actual screening, our docking procedure has been validated. We conducted a test screening using two sets of active test compounds and two sets of decoys. We prepared separate libraries of active CB1 ligands for agonists and antagonists/inverse agonists. Each set contained 25 compounds with Kᵢ values toward human CB1 ≤ 100 nM (Tables S8 and S9). Based on these two sets, we generated two libraries of similar decoys (1250 compounds each) using DUD-E server. Active compounds and decoys were prepared using Schrödinger LigPrep. Decoy sets were filtered based on their physicochemical properties calculated in QikProp, using custom criteria (Table S3). As receptor models, we used CB1 structures based on PDB IDs: STGZ, STGU, SXR8, SXR6, 6N4B, 6KPG, and 6KQL. We performed Glide SP and XP docking (independent of each other) and subsequent MM-GBSA binding free energy calculations. The agonists active and decoys sets were docked to PDB IDs: SXR8, SXR6, 6N4B, 6KPG, and 6KQL, while antagonists to STGZ and STGU. Using Schrödinger Enrichment Calculator, we determined Boltzmann-enhanced discrimination of the receiver operating characteristic (BEDROC) values and EF for docking scores and MM-GBSA ΔGbinding obtained after Glide SP and XP docking (Table S10, Figures S11 and S12 and Supporting Information S2).

Based on the validation results, we conducted docking of the screening compounds to PDB IDs: SXR8 and STGZ. Prior to that, the compounds had been filtered using custom physicochemical criteria different for potential agonists and antagonists (Table S3),
analogically to decoys. Both screening sets were processed using Glide SP, with potential agonists docked to 5XR8 and potential antagonists docked to STG2Z. Finally, potential agonists were docked using Glide XP, while in the case of CB1-potential antagonists complexes, we conducted additional MM-GBSA binding free energy calculations.

4.2.4. Clustering and Analysis. The selected output compounds from docking and MM-GBSA calculations were analyzed for the sake of subsequent in vitro evaluation. We clustered them based on the docking score, and MM-GBSA binding energy. For selected compounds, we analyzed binding poses and protein–ligand interactions in Schrödinger Maestro. The final selection was based on the obtained numerical values, clustering, visual analysis, and purchasability, favoring compounds from diverse structural groups.

4.3. Pharmacological and Toxicological Properties Estimation. Pharmacological properties were estimated using SwissADME server. Water solubility was assessed with ESOL (Estimated Solubility) model. Toxicological properties were computed using Toxtree 3.1.0 and TEST 5.1.0. In Toxtree, the selected models were utilized: Kroes TTC decision tree and in vitro mutagenicity (Ames test) alerts, whereas in TEST—Ames mutagenicity and developmental toxicity.

4.4. In Vitro. 4.4.1. Radioligand Displacement Assay. Compounds selected for the in vitro binding assay from the first iteration of VS were purchased via MolPort, SIA, Riga, Latvia and Biopurify Phytochemicals Ltd., Chengdu, China. Compounds from the second iteration were purchased from MolPort, SIA, Riga, Latvia and Chemspace, SIA, Riga, Latvia (Supporting Information S3). [3H]CP-55,940 and the EcoScint-20 scintillation fluid were purchased from Perkin Elmer (USA). Membranes from cells overexpressing the human CB1 receptor (ChemScreen CB1 Cannabinoid Receptor Membrane Preparation, cat. no. HTS019M) as well as MgCl₂, CaCl₂, Trizma Base, NaCl, polyethyleneimine (PEI) and dimethyl sulfoxide (DMSO) were purchased from Merck (USA). Bovine serum albumin (BSA) was obtained from Pol-Aura (Poland). WIN 55,212-2 mesylate was provided by Tocris Bioscience (UK).

Membrane preparations (2.5 μg protein/tube) from Chem-1 cells expressing human CB1 receptors were incubated in duplicate with 2 nM [3H]CP-55,940 (specific activity: 108.5 Ci/mmol) in a 50 mM Tris-HCl, pH = 7.4 buffer supplemented with 5 mM MgCl₂, 1 mM CaCl₂, 0.2% BSA and increasing concentrations of the compounds tested. Compounds were dissolved in 50% DMSO and added to the reaction mixture at 10⁻⁴ to 10⁻⁴ M. The final DMSO concentration was 5%. Non-specific binding was determined with 100 nM of [³⁵S]GTPγS (specific activity: 1250 Ci/mmol, Perkin Elmer). Specific binding was determined with 100 nM of unlabelled GTPγS. WIN 55,212-2 (3 μM) was used as stimulating ligand. The final DMSO concentration in the assay was 5%. The reaction mixture was incubated for 90 min. at 30°C. Next, the samples were deposited under vacuum with the FilterMate Harvest® (Perkin Elmer, USA) onto Unifilter® GF/B Plates (Perkin Elmer, USA) pre-soaked with wash buffer (50 mM Tris-HCl, pH = 7.4). The samples were then rapidly washed with 2 ml of wash buffer. Filter plates were dried for 30 min. at 50°C and 40 μL of MicroScint PS (Perkin Elmer, USA) scintillation fluid was added to each well. Radioactivity was counted in a Trilux MicroBeta² counter (Perkin Elmer, USA). Data were analyzed with GraphPad Prism 5.0 software. Curves were fitted with three-parameter non-linear regression model. Inhibitory potency (IC₅₀) was calculated and expressed as means from three separate experiments ± 95% confidence intervals (95% CI).

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acschemneuro.2c00502.

4.4.2. [³⁵S]GTPγS Assay. Ten compound concentrations equally spaced on a log scale (10⁻⁵ to 10⁻⁸ M) were incubated in triplicate with membrane preparations from CHO-K1 cells expressing the human CB1 receptor (5 μg per well) (Perkin Elmer, cat. no. ES-110-M400UA) in an assay buffer containing 50 mM Tris-HCl, pH = 7.4, 1 mM EGTA, 3 mM MgCl₂, 100 mM NaCl and 30 μM GDP) in the presence of 0.08 nM [³⁵S]GTPγS (specific activity: 1250 Ci/mmol, Perkin Elmer). Non-specific binding was determined with 100 μM of unlabeled GTPγS. WIN 55,212-2 (3 μM) was used as stimulating ligand. The final DMSO concentration in the assay was 5%. The reaction mixture was incubated for 90 min. at 30°C. Next, the samples were deposited under vacuum with the FilterMate Harvest® (Perkin Elmer, USA) onto Unifilter® GF/B Plates (Perkin Elmer, USA) pre-soaked with wash buffer (50 mM Tris-HCl, pH = 7.4). The samples were then rapidly washed with 2 ml of wash buffer. Filter plates were dried for 30 min. at 50°C and 40 μL of MicroScint PS (Perkin Elmer, USA) scintillation fluid was added to each well. Radioactivity was counted in a Trilux MicroBeta² counter (Perkin Elmer, USA). Data were analyzed with GraphPad Prism 5.0 software. Curves were fitted with three-parameter non-linear regression model. Inhibitory potency (IC₅₀) was calculated and expressed as means from three separate experiments ± 95% confidence intervals (95% CI).

AUTHOR INFORMATION

Corresponding Author
Joanna I. Sulkowska — Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland; orcid.org/0000-0003-2452-0724; Email: j.sulkowska@cent.uw.edu.pl

Authors
Adam Stasiulewicz — Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland; orcid.org/0000-0003-3436-5579
Anna Lesniak — Department of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland
Piotr Setny — Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland; orcid.org/0000-0002-0769-0943
Magdalena Bujalska-Zadrożny — Department of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland

Complete contact information is available at: https://pubs.acs.org/10.1021/acschemneuro.2c00502

Author Contributions
A.S. performed in silico screening and analyzed the data. A.L. performed in vitro assays and analyzed the data. A.S., P.S., and J.S. conceived the study. A.S and A.L. drafted the manuscript. All authors wrote the final submission.

Funding
This work was supported by National Science Centre, Poland grants no. 2019/35/N/NZ7/04258 to AS and no. 2020/01/0/NZ7/00244 to JS.

Notes
The authors declare no competing financial interest.

ABBREVIATIONS
[35S]GTPγS, [35S] guanosine 5’-[γ-thio]triphosphate; AM404, N-arachidonoylaminophenol; BBB, blood–brain barrier; BED-ROC, Boltzmann-enhanced discrimination of the receiver operating characteristic; BSA, bovine serum albumin; CB1, cannabinoid receptor type 1; CI, confidence interval; CryoEM, cryoelectron microscopy; CYP1A2, cytochrome P450 1A2; DMSO, dimethyl sulfoxide; DS, docking score; Emax, maximum effect; EC50, half maximal effective concentration; ECL2, extracellular loop 2; ECS, endocannabinoid system; EF, enrichment factor; ESOL, estimated SOLubility; GAFF, General Amber Force Field; GI, gastrointestinal; IC50, half maximal inhibitory concentration; ICL3, intracellular loop 3; Kp, inhibition constant; LB, ligand-based; MD, molecular dynamics; MM-GBSA, molecular mechanics-generalized Born surface area; MW, molecular weight; NAM, negative allosteric modulator; PDB, Protein Data Bank; PEL, polyethyleneimine; Pgp, P-glycoprotein; POPC, 1-palmitoyl-2-oleoylphosphatidylcholine; QSAR, quantitative structure–activity relationship; rmsd, root-mean-square deviation; SB, structure-based; SEM, standard error of measurement; SP, standard precision; THC, tetrahydrocannabinol; TM, transmembrane (helix); TTC, extra precision; XRD, X-ray diffraction

REFERENCES
(1) Aizpurua-Olayola, O.; Elegarai, I.; Rico-Barrio, I.; Zarandona, I.; Etzabarris, N.; Usobiaga, A. Targeting the Endocannabinoid System: Future Therapeutic Strategies. Drug Discovery Today 2017, 22, 105–110.
(2) Stasiulewicz, A.; Znajdek, K.; Grudzień, M.; Pawiński, T.; Sulkowska, J. I. A Guide to Targeting the Endocannabinoid System in Drug Design. Int. J. Mol. Sci. 2020, 21, 2778.
(3) Mulpuri, Y.; Marty, V. N.; Munier, J. J.; Mackie, K.; Schmidt, B. L.; Seltzman, H. H.; Spigelman, I. Synthetic Peripherally-Restricted Cannabinoid Suppresses Chemotherapy-Induced Peripheral Neuropathy Pain Symptoms by CB1 Receptor Activation. Neuropharmacol. 2018, 139, 85–97.
(4) Sharkey, K. A.; Darmani, N. A.; Parker, L. A. Regulation of Nausea and Vomiting by Cannabinoids and the Endocannabinoid System. Eur. J. Pharmacol. 2014, 722, 134–146.
(5) Sam, A. H.; Salem, V.; Ghatei, M. A. Rimonabant: from RIO to Ban. J. Obes. 2011, 2011, 432607.
(6) Kale, V. P.; Gibbs, S.; Taylor, J. A.; Zmarowski, A.; Novak, J.; Patton, K.; Sparrow, B.; Gorospe, J.; Anand, S.; Cinar, R.; Kunos, G.; Chorvat, R. J.; Terse, P. S. Preclinical Toxicity Evaluation of JD5037, a Peripherally Restricted CB1 Receptor Inverse Agonist, in Rats and Dogs for Treatment of Nonalcoholic Steatohepatitis. Regul. Toxicol. Pharmacol. 2019, 109, 104483.
(7) Fraguas-Sánchez, A. I.; Torres-Suárez, A. I. Medical Use of Cannabinoids. Drugs 2018, 78, 1665–1703.
(8) Bridgeman, M. B.; Abazia, D. T. Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting. P T 2017, 42, 180.
(9) Moreira, F. A.; Grieb, M.; Lutz, B. Central Side-Effects of Therapies Based on CB1 Cannabinoid Receptor Agonists and Antagonists: Focus on Anxiety and Depression. Best Pract. Res., Clin. Endocrinol. Metab. 2009, 23, 133–144.
(10) Chorvat, R. J. Peripherally Restricted CB1 Receptor Blockers. Bioorg. Med. Chem. Lett. 2013, 23, 4751–4760.
(11) Mye, F.; Trezza, V.; Vanderschueren, L. J.; Ramakers, G.; Adan, R. Neutral Antagonism at the Cannabinoid 1 Receptor: A Safer Treatment for Obesity. Mol. Psychiatry 2013, 18, 1294–1301.
(12) Nguyen, T.; Li, J.-X.; Thomas, B. F.; Wiley, J. L.; Kenakin, T. P.; Zhang, Y. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Med. Res. Rev. 2017, 37, 441–474.
(13) Ottani, A.; Leone, S.; Sandrini, M.; Ferrari, A.; Bertolini, A. The Analgesic Activity of Paracetaolm is Prevented by the Blockade of Cannabinoid CB1 Receptors. Eur. J. Pharmacol. 2006, 531, 280–281.
(14) Sharma, C. V.; Long, J. H.; Shah, S.; Rahman, J.; Perrett, D.; Ayoub, S. S.; Mehta, V. First Evidence of the Conversion of Paracetamol to AM404 in Human Cerebrospinal Fluid. J. Pain Res. 2017, 10, 2703.
(15) Cronull, F.; Vilela, F. C.; Giusti-Paiva, A. Cannabinoid CB1 Receptors Mediate The Effects of Dipyrene. Clin. Exp. Pharmacol. Physiol. 2015, 42, 246–255.
(16) Priestley, R. S.; Nickolls, S. A.; Alexander, S. P.; Kendall, D. A. A Potential Role for Cannabinoid Receptors in the Therapeutic Action of Fenofibrate. EASEF J. 2015, 29, 1446–1455.
(17) Franks, L. N.; Ford, B. M.; Prather, P. L. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Front. Pharmacol. 2016, 7, 503.
(18) Abrams, D. I. The Therapeutic Effects of Cannabis and Cannabinoids: An Update from the National Academies of Sciences, Engineering and Medicine Report. Eur. J. Intern. Med. 2018, 49, 7–11.
(19) Kumar, P.; Mahato, D. K.; Kamle, M.; Borah, R.; Sharma, B.; Pandhi, S.; Tripathi, V.; Yadav, H. S.; Devi, S.; Patil, U.; Xiao, J.; Mishra, A. K. Pharmacological Properties, Therapeutic Potential, and Legal Status of Cannabis Sativa L.: An Overview. Phytother. Res. 2021, 35, 6010–6029.
(20) Russo, E. B. Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol. Sci. 2016, 37, 594–605.
(21) Hua, T.; Vemuri, K.; Pu, M.; Qu, L.; Han, G. W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.; Laprairie, R. B.; Stahl, E. L.; Ho, J.-H.; Zvonok, N.; Zhou, H.; Kufareva, I.; Wu, B.; Zhao, Q.; Hanson, M. A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z.-J. Crystal Structure of the Human Cannabinoid Receptor CB1. Cell 2016, 167, 750–762.
(22) Shao, Z.; Yin, J.; Chapman, K.; Grzemska, M.; Clark, L.; Wang, J.; Rosenbaum, D. M. High-Resolution Crystal Structure of the Human CB1 Cannabinoid Receptor. Nature 2016, 540, 602–606.
(23) Hua, T.; Vemuri, K.; Nikas, S. P.; Laprairie, R. B.; Wu, Y.; Qu, L.; Pu, M.; Korde, A.; Jiang, S.; Ho, J.-H.; Han, G. W.; Ding, K.; Li, X.; Liu, H.; Hanson, M. A.; Zhao, S.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z.-J. Crystal Structures of Agonist-Bound Human Cannabinoid Receptor CB1. Nature 2017, 547, 468–471.
(24) Kumar, K. K.; Shalay-Benami, M.; Robertson, M. J.; Hu, H.; Banister, S. D.; Hollingsworth, S. A.; Latorraca, N. R.; Kato, H. E.; Hilger, D.; Maeda, S.; Weis, W. I.; Farrens, D. L.; Droot, R. O.; Malhotra, S. V.; Koblika, B. K.; Skiniotis, G. Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex. Cell 2019, 176, 448–458.

(25) Shao, Z.; Yan, W.; Chapman, K.; Ramesh, K.; Ferrell, A. J.; Yin, J.; Wang, X.; Xu, Q.; Rosenbaum, D. M. Structure of an Allosteric Modulator Bound to the CB1 Cannabinoid Receptor. Nat. Chem. Biol. 2019, 15, 1199–1205.

(26) Hua, T.; Li, X.; Wu, L.; Ilipoulos-Tsoutsouvas, C.; Wang, Y.; Wu, M.; Shen, L.; Johnston, C. A.; Nikas, S. P.; Song, F.; Song, X.; Yuan, S.; Sun, Q.; Wu, Y.; Jiang, S.; Grim, T. W.; Benchama, O.; Stahl, E. L.; Zvonok, N.; Zhao, S.; Bohn, L. M.; Makriyannis, A.; Liu, Z.-J. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures. Cell 2020, 180, 655–665.

(27) Wang, X.; Liu, D.; Shen, L.; Li, F.; Li, Y.; Yang, L.; Xu, T.; Tao, H.; Yao, D.; Wu, L.; Hirata, K.; Bohn, L. M.; Makriyannis, A.; Liu, X.; Hua, T.; Liu, Z.-J.; Wang, J. A Genetically Encoded F-19 NMR Probe Reveals the Allosteric Modulation Mechanism of Cannabinoid Receptor 1. J. Am. Chem. Soc. 2021, 143, 16320–16325.

(28) Davies, M.; Nowotka, M.; Papadatos, G.; Dedman, N.; Gaulton, A.; Atkinson, F.; Bellis, L.; Overington, J. P. ChEMBL Web Services: Streamlining Access to Drug Discovery Data and Utilities. Nucleic Acids Res 2015, 43, W612–W620.

(29) Mendez, D.; Gaulton, A.; Bento, A. P.; Chambers, J.; De Veij, M.; Felix, E.; Magariños, M. P.; Mosquera, J. F.; Mutowpo, P.; Nowotka, M.; Gordillo-Marañón, M.; Hunter, F.; Junco, L.; Mugumbate, G.; Rodriguez-Lopez, M.; Atkinson, F.; Bosc, N.; Radox, C. J.; Segura-Cabrera, A.; Hersey, A.; Leach, A. R. ChEMBL: Towards Direct Deposition of Bioassay Data. Nucleic Acids Res 2019, 47, D930–D940.

(30) Cinar, R.; Iyer, M. R.; Kunos, G. The Therapeutic Potential of Second and Third Generation CB1R Antagonists. Pharmacol. Ther. 2020, 208, 107477.

(31) Li, Q.; Ye, T.; Long, T.; Peng, X. Ginkgetin Exerts Anti-Inflammatory Effects on Cerebral Ischemia/Reperfusion-Induced Injury in a Rat Model via the TLR4/NF-κB and NFAT Pathways. Front. Pharmacol. 2019, 10, 3136.

(32) Kato, H. E.; Hilger, D.; Wang, X.; Wang, W. A.; Weis, W. I.; Farrens, D. L.; Droot, R. O.; Malhotra, S. V.; Koblika, B. K.; Skiniotis, G. Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex. Cell 2019, 176, 448–458.

(33) Anwar, H.; Sarfraz, I.; Riaz, A.; Manzoor, M.; Adem, S.; Selamoglu, Z.; Ginkgetin: A Natural Biflavone With Versatile Pharmacological Activities. Food Chem. Toxicol. 2020, 145, 11642.

(34) Ben-Sabat, S.; Sfez, E.; Sheskin, T.; Tamir, T.; Rhee, M.-H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzo, V.; Mechoulam, R. An Entourage Effect: Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-Arachidonoyl-glycerol Cannabinoid Activity. Eur. J. Pharmacol. 1998, 353, 23–31.

(35) Russo, E. B. Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. Br. J. Pharmacol. 2011, 163, 1344–1364.

(36) Paronis, C. A.; Nikas, S. P.; Shukla, V. G.; Makriyannis, A. Δ9-Tetrahydrocannabinol Acts as a Partial Agonist/Antagonist in Mice. Behav. Pharmacol. 2012, 23, 802.

(37) Zhu, X.; Li, Y.; Xu, T.; Tao, H.; Yao, D.; Wu, L.; Hirata, K.; Bohn, L. M.; Makriyannis, A.; Liu, X.; Hua, T.; Liu, Z.-J.; Wang, J. A Genetically Encoded F-19 NMR Probe Reveals the Allosteric Modulation Mechanism of Cannabinoid Receptor 1. J. Am. Chem. Soc. 2021, 143, 16320–16325.

(38) Brunt, T. M.; Bossong, M. G. The Neuropharmacology of Cannabinoid Receptor Ligands in Central Signaling Pathways. Eur. J. Neurosci. 2022, 55, 909–921.

(39) Alig, L.; Alsenz, J.; Andjelkovic, M.; Bendels, S.; Bénardeau, A.; Bénard, T.; Roussel, E.; Hildbrand, S.; Mayweg, A. V.; Narquizian, R.; Neidhart, W.; Burt, D.; Schulz, T.; Roberts, D.; Shen, J.; Kromidas, L.; Api, A. M. Comparison of Cramer Classification Between Toxtree, the OECD QSAR Toolbox and Expert Judgment. Regul. Toxicol. Pharmacol. 2015, 71, 52–62.

(40) Carns, E. A.; Baldridge, W. H.; Kelly, M. E. M. The Endocannabinoid System as a Therapeutic Target in Glaucoma. Neural Plast. 2016, 2016, 9364091.

(41) Miller, S.; Daily, L.; Ploss, M.; Greig, I.; Ross, R.; Rayana, N. P.; Dai, J.; Sugali, C. K.; Mao, W.; Straiker, A. Evidence that Cannabinoid CB1 Receptors Regulate Intracellular Pressure via Two Opposing Mechanisms. Exp. Eye Res. 2020, 200, 108241.

(42) Adnan, M.; Rasul, A.; Hussain, G.; Shah, M. A.; Zahoor, M. K.; Anwar, H.; Sarfraz, I.; Riaz, A.; Manzoor, M.; Adem, S.; Selamoglu, Z.; Ginkgetin: A Natural Biflavone With Versatile Pharmacological Activities. Food Chem. Toxicol. 2020, 145, 11642.
(59) Abraham, M. J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J. C.; Hess, B.; Lindahl, E. GROMACS: High Performance Molecular Simulations Through Multi-Level Parallelism from Laptops to Supercomputers. SoftwareX 2015, 1, 19–25.

(60) Sterling, T.; Irwin, J. J. ZINC 15—Ligand Discovery for Everyone. J. Chem. Inf. Model. 2015, 55, 2324–2337.

(61) Wu, G.; Robertson, D. H.; Brooks, C. L.; Vieth, M. Detailed Analysis of Grid-Based Molecular Docking: A Case Study of CDOCKER—A CHARMM-based MD Docking Algorithm. J. Comput. Chem. 2003, 24, 1549–1562.

(62) Muegge, I. PMF Scoring Revisited. J. Med. Chem. 2006, 49, 5895–5902.

(63) Consortium, UniProt UniProt: A Worldwide Hub of Protein Knowledge. Nucleic Acids Res 2019, 47, DS06–DS15.

(64) Jo, S.; Kim, T.; Iyer, V. G.; Im, W. CHARMM-GUI: A Web-Based Graphical User Interface for CHARMM. J. Comput. Chem. 2008, 29, 1859–1865.

(65) Case, D. A., Ben-Shalom, I. Y., Brozell, S. R., Cerutti, D. S., Cheatham, T. E., Crozzeiro, V. W. D., Darden, T. A., Duke, R. E., Ghoreishi, D., Gibson, M. K., et al. AMBER 2018. University of California, San Francisco, 2018.

(66) Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and Testing of a General Amber Force Field. J. Comput. Chem. 2004, 25, 1157–1174.

(67) Lindorff-Larsen, K.; Piana, S.; Maragakis, P.; Klepeis, J. L.; Dror, R. O.; Shaw, D. E. Improved Side-Chain Torsion Potentials for the Amber ff99SB Protein Force Field. Proteins: Struct., Funct., Bioinf. 2010, 78, 1950–1958.

(68) Dickson, C. J.; Madej, B. D.; Skjervik, Å. Å.; Betz, R. M.; Teigen, K.; Gould, I. R.; Walker, R. C. Lipid14: The Amber Lipid Force Field. J. Chem. Theory Comput. 2014, 10, 865–879.

(69) Humphrey, W.; Dalke, A.; Schulten, K. VMD—Visual Molecular Dynamics. J. Mol. Graphics Modell. 1996, 14, 33–38.

(70) Groesbeck, J. L.; Perry, J. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47, 1750–1759.

(71) Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. J. Med. Chem. 2012, 55, 6582–6594.

(72) Athanasiadis, E.; Cournia, Z.; Spyrou, G. ChemBioServer: A Web-Based Pipeline for Filtering, Clustering and Visualization of Chemical Compounds Used in Drug Discovery. Bioinformatics 2012, 28, 3002–3003.

(73) Abraham, M. J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J. C.; Hess, B.; Lindahl, E. GROMACS: High Performance Molecular Simulations Through Multi-Level Parallelism from Laptops to Supercomputers. SoftwareX 2015, 1, 19–25.

(74) Sterling, T.; Irwin, J. J. ZINC 15—Ligand Discovery for Everyone. J. Chem. Inf. Model. 2015, 55, 2324–2337.

(75) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. J. Med. Chem. 1997, 40, 779–817.

(76) Sterling, T.; Irwin, J. J. ZINC 15—Ligand Discovery for Everyone. J. Chem. Inf. Model. 2015, 55, 2324–2337.

(77) Abraham, M. J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J. C.; Hess, B.; Lindahl, E. GROMACS: High Performance Molecular Simulations Through Multi-Level Parallelism from Laptops to Supercomputers. SoftwareX 2015, 1, 19–25.

(78) Groesbeck, J. L.; Perry, J. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47, 1750–1759.

(79) Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. J. Med. Chem. 2012, 55, 6582–6594.

(80) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.

(81) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.

(82) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.

(83) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.

(84) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.

(85) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.

(86) Patlewicz, G.; Jeliázková, N.; Safford, R.; Worth, A.; Aleksiev, B. A. An Evaluation of the Implementation of the Cramer Classification Scheme in the Toxtree Software. SAR QSAR Environ. Res. 2008, 19, 495–524.